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Abstract:  Current diagnostics for lysosomal storage disorders such as 
mucopolysaccharidosis (MPS) rely on evaluation of ex vivo bodily fluids, 
which has several shortcomings. In this study, we evaluated whether Raman 
spectroscopy could noninvasively diagnose MPS in a murine model. Via 
confocal sampling of the murine outer ear, Raman spectra were obtained at 
multiple depths. Partial least-squares discriminant analysis of the processed 
Raman spectra showed a 93% sensitivity and 91% specificity for disease. 
The discriminant algorithm relied on several Raman bands related to 
glycosaminoglycans (GAGs) that typically accumulate in MPS. These 
findings indicate the possibility for a new, noninvasive diagnostic tool for 
MPS. 
©2011 Optical Society of America 
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1. Introduction 
The mucopolysaccharidoses (MPS) are a family of genetic disorders within the greater 
umbrella of lysosomal storage diseases. These diseases are linked by a deficiency in 
lysosomal hydrolases that catalyze the degradation of glycosaminoglycans (GAGs). As a 
result, GAGs that are normally recycled in a healthy individual cannot be degraded in the 
MPS patient. Undegraded GAGs are accumulated in cells and can adversely affect the tissue 
(e.g. cartilage, bone, kidney) function [1,2]. MPS type I (MPS-I) is one of the most prevalent 
forms of the MPS disease, usually denoted as Hurler’s syndrome in more severe 
manifestations and Scheie’s syndrome when less severe. MPS-I is the result of a deficiency in 
the iduronidase enzyme, wherein the specific GAGs that accumulate in the tissues are heparin 
sulfate and dermatan sulfate [3,4]. 
Conventional methods for measuring GAG accumulation rely on patient fluids (urine or 
blood), which indicate systemic GAG concentrations and lack tissue specificity [5–7]. 
Measurement of GAGs is performed at a small number of specialty laboratories nationwide 
and generally requires days to weeks turnaround time, delaying diagnosis and initiation of 
treatment. Furthermore, systemic GAG concentrations can be unreliable for the monitoring of 
disease progression or efficacy of treatment; once treated with enzyme replacement therapy 
(ERT) or hematopoietic stem cell transplantation (HSCT), a patient’s systemic GAG levels 
decline to near-normal levels while obvious disease progression continues in skeletal, cardiac, 
and other systems [8]. Based on these shortcomings, the development of a new technique for 
noninvasive diagnosis of MPS disease involvement and quantification of treatment response is 
obviously warranted. 
Raman spectroscopy is an optical technique for molecular analysis that has been used 
extensively in various biomedical applications [9–12]. These studies have shown that Raman 
spectroscopy is capable of detecting subtle changes in tissue biochemistry to allow 
noninvasive diagnosis of pathology. More importantly, Raman spectra can be obtained at 
resolved depth, via standard optical modalities such as confocal [13,14] or separated source-
detector [15,16], to allow the biochemical characterization of subsurface anatomic structures. 
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Raman spectrum [17–20], which indicates the potential to detect these GAGs within the tissue 
milieu. 
Based on the demonstrated capabilities of Raman spectroscopy and the demonstrated need 
for new MPS diagnostics, we evaluated in this study the Raman technique’s ability to provide 
noninvasive diagnosis of MPS-I in a murine model. This preliminary data and previous 
successes in the use of Raman spectroscopy for other biomedical applications suggest that the 
Raman technique may provide diagnostic value in the clinical management of MPS. 
2. Materials and methods 
This study was performed using the MPS-I murine model described in [21] bred into a NOD-
SCID-IL2Rγ (NSG) background [22]. In brief, this model is created by genetic knockout of α-
L-iduronidase (IDUA), manifesting in visually apparent phenotypic response by 
approximately 4 weeks of age. Seven IDUA knockout mice (termed “disease” population) and 
five wild type mice (termed “normal” population) were evaluated as part of this study. The 
outer ear was clipped from the animals immediately after sacrifice for population control of an 
existing study, snap frozen in liquid nitrogen and stored at −80 °C until the time of optical 
measurement. The age and genotype of the animals studied is included in Table 1. Upon time 
of optical measurement, the samples were passively thawed in PBS for ~15 minutes at room 
temperature to avoid any spectral artifacts related to freeze/thaw [23]. Dermatan and heparan 
sulfates were obtained in dried, purified form (Sigma Aldrich, St. Louis, MO) and 
characterized on the same measurement system. 
Table 1. Genotype and age (at time of sacrifice) of mice 
Sample  Age (months)  IDUA genotype 
1  13.8  −/− 
2  9.4  −/− 
3  9.4  −/− 
4  7.7  −/− 
5  7.5  −/− 
6  4.1  −/− 
7  13.8  −/− 
8  13.8  +/+ 
9  4.1  +/+ 
10  13.5  +/+ 
11  10  +/+ 
12  10  +/+ 
Spectra were obtained using a confocal Raman microspectrometer (RM1000, Renishaw 
PLC, Wotton-under-Edge, UK). This system is based on an upright microscope with attached 
spectrometer. The laser emits in the near-infrared region (785 nm) and the sample is exposed 
through a 50 × , 0.55 NA objective (LMPlan IR, Olympus Corp., Center Valley, PA) with 40 
mW power at the sample focused into a spot. The light was collected in the epi-direction and 
detected using a CCD camera with a slit aperture to maintain system confocality. Using a 100 
mm slit width in the spectrometer, the spatial resolution of the system is ~2 μm laterally and 
~ 4  μ m  a x i a l l y ,  a s  d e t e r m i n e d  b y  t h e  f u l l -width-at-half-max of the spectra obtained by 
scanning a 1 μm polystyrene bead in 3 dimensions. 
Raman spectra were measured from the skin surface down to depth of 200 µm in 
increments of 20 µm. Measurements were made in randomly selected locations within the 
central portion of the outer ear samples, where the cross-section shows a generally uniform 
dimension among the strata. All spectra were obtained with a 60 second integration time in 
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−1. For each experiment, spectral dispersion was calibrated 
using a neon-argon lamp, wavenumber shift calibration was performed using acetaminophen 
as a reference standard, and system response was calibrated using a doped glass standard 
(NIST 2241). Higher frequency readout and shot noise was removed by a second-order 
Savitzky-Golay smoothing filter. Tissue autofluorescence was subtracted via an automated 5th 
order modified polynomial fitting method using the full wavenumber range [24]. The 
processed spectra were binned to 5 cm
−1  and normalized to four different normalizations 
schemes: the mean normalized intensity of the entire spectrum (600-1700 cm
−1), the 1003 
cm
−1  peak (phenylalanine ring vibration) intensity, the 1443 cm
−1  peak (CH2  bend of 
proteins/lipids) intensity, and the 1658 cm
−1 peak (Amide I stretch of proteins/lipid) intensity, 
all of which have been recommended based on previous comparative studies [25,26]. All 
normalization methods were carried through subsequent analysis. 
The preprocessed spectra were analyzed using partial least squares discriminant analysis 
(PLSDA, PLS Toolbox Version 6.2.1, Eigenvector Research Inc., Wenatchee, WA) in the 
Matlab (Mathworks Inc., Natick, MA, Version R2010a) programming environment. To ensure 
robust results, cross validation was done using multiple (20) iterations of random subset 
withholding (leave 10% out). Sample scores were used to assess diagnostic accuracy of the 
Raman spectra, using decision lines that maximized separation of the normal and disease 
populations. Because there were only two classes evaluated, the calculated sensitivity and 
specificity values are interchangeable. 
3. Results and discussion 
 
Fig. 1. Top: Mean Raman spectra of all normal and disease samples, with shaded boundary of ( 
± ) standard deviation. Bottom: Difference spectrum (disease minus normal) obtained from the 
mean spectra reveal a number of band differences between the populations. 
The Raman spectra of both normal and disease populations are shown in Fig. 1 (normalized to 
CH2 bending mode of proteins and lipids at 1443 cm
−1, as described below). Qualitatively, 
there are spectral differences between the two populations that can be more readily visualized 
in the difference spectra (bottom plot of Fig. 1). The most significant differences are seen in 
the protein and lipid Raman band regions and in the spectral features of the functional groups 
of disease-relevant sulfated GAGs. 
The most apparent difference is observed in the increased intensity of diseased tissue 
amide III band region around 1240-1300 cm
−1, the CH3 symmetric deformation band at 1377 
cm
−1, the symmetric ring at 1002 cm
−1  and C-H bending at 1032 cm
−1  of phenylalanine 
[11,12]. In regions of GAG Raman activity, the spectra are most different in the glycosidic 
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−1  [18] (also attributed to C–C stretching of 
proline/valine amino acid), and the 822 cm
−1 and 852 cm
−1 peaks attributed to asymmetric 
vibration of the C-O-S linkage, which has also been attributed to tyrosine/proline amino acid 
[11,12]. There are also slight differences seen at amide I proteins and lipids band at 1658 
cm
−1, symmetric stretch of the sulfate group (OSO3
-) at 1062 cm
−1, and C-OH deformation at 
1127 cm
−1. The attributions of the dominant peaks in the measured spectra are summarized in 
Table 2, with band assignments derived from the literature. Generally, disease tissues show an 
increase in all major GAG vibrations as well as proline, valine, and phenylalanine amino 
acids, when the spectra is normalized to structural proteins and lipids (1443 cm
−1 or 1658 cm
−1 
peaks). 
Table 2. Major vibrational modes observed in normal and diseased mouse ear Raman 
spectra and sulfated glycosaminoglycans
a 
Band (cm
−1)  Assignment 
822  Asymmetric C-O-S linkage vibration of GAGs, Tyrosine/O–P–O stretch of DNA 
852  Asymmetric C-O-S linkage vibration of GAGs, Tyrosine and C–C stretch of proline ring 
877  C-H deformation for β anomers 
937  Glycosidic linkage C-O-C vibration in GAGs, C–C stretch of proline/valine and protein backbone 
1002  Symmetric ring of phenylalanine 
1032  C–H bending of phenylalanine 
1062  OSO
-
3 symmetric stretch from sulfate group of GAGs 
1082  C–N stretch of proteins and lipid, and C-OH deformation 
1127  C–C stretching of lipids, C–N protein stretch, C-H and C-OH deformation 
1240–1300  Amide III (C–N stretch of proteins) 
1337  CH3CH2 wagging of collagen, polynucleotide chain and phenylalanine 
1443  CH2 bending of proteins and lipids 
1658  Amide I (C = O stretching of proteins), C = C lipid stretch 
aFrom [11,12,18] 
To illustrate the spectral dependence on measurement depth, Fig. 2 shows a depth-series-
plot of the mean Raman spectra obtained from the 2 oldest animals of each population 
(animals 1, 7, 8, and 10; displayed depths are reduced for clarity). Epidermal measurements 
(surface to ~20 µm) produce relatively subtle spectral differences between the normal and 
diseased tissues. However, 60 µm and deeper measurements produce much more significant 
disparity between the population spectra, with increased intensity in the diseased tissues at all 
the major GAG and amino acid peaks (857, 922, 937, 1003, 1032, 1062, 1247 cm
−1). There is 
also a decreased signal at the 1658 cm
−1 Amide I peak for diseased tissue compared to normal, 
as well as a possible conformational change shifting the 1443 cm
−1 CH2 bending mode (to 
~1453 cm
−1). Thus, there is a discernable unique chemical process occurring in the deeper 
layers (dermis, cartilage) versus the superficial skin layers. This is reasonable, given the 
general manifestation of GAGs and associated accumulation in cartilaginous structures of the 
MPS patient. Morphometric analysis of a stained cross section of one of the ears studied here 
showed a dermal thickness (stratum corneum through dermis) of approximately 40-100 µm on 
both sides of a central cartilage layer of ~50 µm thickness. This finding is important for future 
clinical evaluations of Raman spectroscopy for MPS disease characterization, as such a 
clinical system will benefit from a deeper interrogation depth and possibly a combined 
imaging technique to allow determination of subsurface anatomy. 
The PLSDA scores plot of the Raman spectra are shown in Fig. 3, which reveals a distinct 
difference in scattering between the two populations. On inserting a decision line between the 
2 populations, 64 of 70 disease measurements and 46 of 50 normal measurements could be 
correctly classified, resulting in 93% sensitivity and 91% specificity for disease. Using the  
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Fig. 2. Mean Raman spectra of disease and normal tissues at different measured depth. Marked 
differences are seen between the two tissue types at depths greater than ~60 µm. 
majority diagnosis for all the spectra obtained from each animal, this translates to accurate 
diagnosis of 6 of 7 diseased and 5 of 5 normal animals. The 1 misclassified diseased animal in 
this analysis happened to be 7.5 months of age and it not clear yet the cause of this 
discrepancy. However, if only the measurements obtained from subdermal depths (~60 µm- 
140 µm) are utilized, all animals are correctly diagnosed. Indeed, all the major discrepancies 
in the score plot for both disease and normal populations are observed either in the superficial 
skin measurements or very deep in the tissue (~180 µm), where the symmetric profile of the 
ear cross-section would result in measurement of the opposite skin layer. 
To determine which spectral features are most diagnostically relevant, the loading plots of 
the PLSDA were evaluated, as seen in Fig. 4. The figure also shows the Raman spectra of 
purified salts of dermatan and heparan sulfates, exhibiting the major Raman peaks present in 
the sulfated GAGs typically elevated in MPS-I for comparison. Major differences in the 
Raman peaks are seen at 867, 942, 977, 1062, 1082, 1122, 1237, 1342, 1412, 1657 cm
−1, most 
of which were identified in the difference spectra and attributed in Table 2. For direct 
comparison with the sulfated GAGs, the spectral bands of diagnostic significance are 
highlighted by dotted lines. 
The choice of normalization scheme proved to  be an important consideration, as 
demonstrated by previous comparative studies [25,26]. Following each scheme through 
discriminant analysis, normalization to the 1443 cm
−1 peak provided maximum sensitivity and 
specificity (93% and 91%, respectively), followed closely by normalization to the 1658 cm
−1 
peak (92% and 90%) and mean (87% and 92%), while 1003 cm
−1 peak normalization yielded 
a much poorer performance (84% and 75%). Qualitatively, the schemes based on the 
dominant 1443 and 1658 cm
−1 bands resulted in an overall elevation of the GAG bands in  
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Fig. 3. Discriminant function scores (from PLSDA) for all measured spectra, showing a 
separation of the two populations with 93% sensitivity and 91% specificity. 
 
Fig. 4. (Top) Raman spectra of purified dermatan and heparan sulfate GAGs. (Bottom) The 
loading plots of the five latent variables from PLSDA of the spectral data from both normal and 
diseased measurements. Spectral peaks of the most prominent resemblance are indicated by 
dotted lines. 
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−1 schemes produced a 
relative mix in GAG peak intensities between the populations. This is likely to cause the 
difference in diagnostic accuracy, and is an important consideration for future studies. 
While the use of excised tissues that were previously frozen is not as desirable as the study 
of intact, living tissues, the results obtained here demonstrate the Raman technique’s capacity 
to accurately diagnose MPS. By immediately freezing the samples after collection and 
studying the passively thawed samples within a reasonable time, it is expected that in-vivo 
measurements would provide comparable diagnostic success [23]. The study of outer ear was 
selected due to the thin skin covering of a central cartilaginous region, thereby providing 
relatively simple optical access to a site of GAG accumulation. The outer ear is also a useful 
target for future clinical studies for the same reasons and because of the easy anatomic access 
for an optical instrument. While this study utilized ears that had been clipped for ease of 
experimental study (minimizing restraint, anesthesia, etc.), the Raman technique is easily 
made portable and employable via fiber optic means, which would allow its noninvasive 
interrogation of the tissue to be utilized in clinical environments. Further studies are currently 
underway to characterize the Raman technique’s ability to quantify GAG concentrations for 
possible identification of disease severity and treatment response. These studies will also 
evaluate different anatomic measurement sites, such that tissue-level interrogation can be 
performed. 
4. Conclusion 
Nearly all standard care and research techniques for MPS diagnosis rely on ex vivo analysis of 
patient fluids including blood or urine. These approaches offer only systemic measurement of 
the GAGs which accumulate as a process of the disease. In this paper, we have shown that 
optical spectroscopy can provide accurate diagnosis of MPS by interrogation of intact tissues. 
The benefits of this approach are its noninvasiveness, lack of fluid handling, and tissue 
specificity. Furthermore, because of the specific bands of the GAGs that present in the bulk 
tissue spectra, this approach may offer the ability to quantify GAG concentrations in various 
tissue volumes. Thus, optical spectroscopy may offer a new, accurate diagnostic and metric of 
lysosomal storage diseases such as MPS. 
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